Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aumolertinib - Jiangsu Hansoh Pharmaceutical

Next Previous
Drug Profile

Aumolertinib - Jiangsu Hansoh Pharmaceutical

Alternative Names: Almonertinib; AMEILE; Amerol; Aumolertinib mesylate - Jiangsu Hansoh Pharmaceutical; Aumseqa; EQ-143; HS-10206; HS-10296; HS-10296 mesylate

Latest Information Update: 01 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Developer EQRx; Henan Cancer Hospital; Jiangsu Hansoh Pharmaceutical
  • Class Acrylamides; Amines; Antineoplastics; Cyclopropanes; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • No development reported Meningeal carcinomatosis; Solid tumours

Most Recent Events

  • 16 Dec 2025 Glenmark Pharmaceuticals Ltd enters into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical to develop and commercialize aumolertinib across its licensed territories
  • 16 Dec 2025 Registered for Non-small cell lung cancer (Metastatic disease, Late-stage disease, First-line therapy) in United Kingdom (PO)
  • 12 Dec 2025 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of Aumolertinib for Non-small cell lung cancer in the European Union prior to December 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top